Inequalities in access to cancer screening programmes in Spain and how to reduce them: data from 2013 and 2020
Por:
Molina-Barceló A, Moreno Salas J, Peiró-Pérez R, Arroyo G, Ibáñez Cabanell J, Vanaclocha Espí M, Binefa G, García M and Salas Trejo D
Publicada:
26 ene 2021
Ahead of Print:
26 ene 2021
Resumen:
Background: The European Commission recommends ensuring equity in cancer screening. The aim of this study was to find out if there were inequalities in access to cancer screening programmes in Spain.
Methods: A transversal study was carried out by means of a survey addressed to the people responsible for breast, colorectal (CRC) and cervical cancer screening programmes in the 19 Autonomous Communities (AC) of Spain in 2013 and 2020. Information was collected on organizational characteristics. inequalities in access and interventions to reduce them. A descriptive analysis was made by AC and time period, by calculating frequencies and percentages. depending on the type of programme (breast, CRC and cervix).
Results: In 2013, 14 ACs participated for the breast programme. 8 for the CRC and 7 for the cervical programme; and in 2020, 14, 13 and 11 ACs respectively. All breast programmes were population-based in both periods (14/14 in 2013 and 14/14 in 2020). as well as CRC ones (8/8 in 2013 and 13/13 in 2020), with an increase in cervical cancer programmes (0/7 en 2013 y 611 en 2020). In both periods, social groups not included in the target population and groups that were less involved were identified, with differences according to the type of programme. A total of 53 interventions were carried out to reduce inequalities in access (27 in breast, 22 in RCC and 4 in cervical), 66% of them aimed at specific social groups (35/53).
Conclusions: Inequalities in access to cancer screening programmes in Spain are identified, as well as interventions to reduce them.
Filiaciones:
:
Área de Cáncer y Salud Pública. FISABIO-Salud Pública. Valencia. España
Moreno Salas J:
Área de Cáncer y Salud Pública. FISABIO-Salud Pública. Valencia. España
:
Área de Cáncer y Salud Pública. FISABIO-Salud Pública. Valencia. España
Dirección General de Salud Pública y Adicciones. Consellería de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia. España
Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP). Madrid. España
Arroyo G:
Dirección General de Salud Pública y Adicciones. Consellería de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia. España
:
Área de Cáncer y Salud Pública. FISABIO-Salud Pública. Valencia. España
Dirección General de Salud Pública y Adicciones. Consellería de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia. España
:
Área de Cáncer y Salud Pública. FISABIO-Salud Pública. Valencia. España
Binefa G:
Instituto Catalán de Oncología. IDIBELL. Hospitalet de Llobregat. España
García M:
Instituto Catalán de Oncología. IDIBELL. Hospitalet de Llobregat. España
:
Área de Cáncer y Salud Pública. FISABIO-Salud Pública. Valencia. España
Dirección General de Salud Pública y Adicciones. Consellería de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia. España
Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP). Madrid. España
|